Citius Oncology Reports 120% Growth in LYMPHIR Shipments
3 The company announced a 120% increase in LYMPHIR unit sales for Q4 2026 fueled by expanded commercial reach. The preliminary data indicates strong institutional demand and successful coverage expansion for the CTCL treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed